Viewing data from:

POTASSIUM CITRATE

ANDA

POTASSIUM CITRATE | A212779 | ANI PHARMACEUTICALS INC

2 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: UROCIT-K(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$0.1813

per ea

Lowest NADAC/Unit

$0.1796

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
62559029101POTASSIUM CITRATE ER 10 MEQ TB	$0.1813	EA	Generic	—	2026-06-17
62559029201POTASSIUM CITRATE ER 15 MEQ TB	$0.1796	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain2 active DMFs1 inactive

2 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

TAPI NL BVPOTASSIUM CITRATE USP

DMF 310682016

GLOBAL CALCIUM PRIVATE LTDPOTASSIUM CITRATE USP

DMF 368752022

ARCHER DANIELS MIDLAND COInactivePOTASSIUM CITRATE MONOHYDRATE

DMF 103011993

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 10MEQ

0 patents0 exclusivities▴

TABLET, EXTENDED RELEASE;ORAL | Approved: Jan 14, 2020

No patent or exclusivity listings for this strength.

#002 — 15MEQ

0 patents0 exclusivities▾

TABLET, EXTENDED RELEASE;ORAL | Approved: Jan 14, 2020